No, that is very true (LOL)... "He wouldnt want to tell a crap...

No, that is very true (LOL)... "He wouldnt want to tell a crap story to the world?"... and he won't be come Dec 9.

The story of PTX-100 will soon be presented to those where the science will speak the loudest anyway.

Re the PD-PK analysis data in context of the dose escalations, the abstract speaks volumes already - https://ash.confex.com/ash/2023/webprogram/Paper179411.html

Inhibition of RAP1 GG was observed with all doses including the lowest dose of 500 mg/m2.

PK analysis is underway at the time of abstract preparation and the PK parameters will be presented at the meeting.

Conclusions: Preliminary data from this phase 1 dose escalation study of PTX-100 indicates promising safety profile in this difficult to treat pt population. PTX-100 demonstrated clinical activity in TCL with an ORR of 40%, and a median PFS for all TCL pts of 5.3 months. PD studies demonstrated that the GGT-1 target was engaged with sustained inhibition of RAP1 GG.

It was good to hear that more patients have been recruited (if I heard correctly). So, its likely that further data will be added to the oral presentation and that the ruling off of data for the FDA meeting will be beyond the date of the ASH conference.